An open-label, phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors. This is an ASCO Meeting ...
Molecular markers associated with survival in PD-L1– high non-small cell lung cancer treated with first-line immunotherapy versus chemoimmunotherapy. This is an ASCO Meeting Abstract from the 2025 ...
Oral potentially malignant disorders (OPMDs), characterized by a wide variety of types and diverse clinical manifestations, have always been difficult to diagnose and differentiate. All of them carry ...
Start working toward program admission and requirements right away. Work you complete in the non-credit experience will transfer to the for-credit experience when you ...
NASHVILLE--(BUSINESS WIRE)-- HealthStream (Nasdaq: HSTM), a leading healthcare technology platform for workforce solutions, today announces the launch of the HealthStream Learning Experience™ (HLX), ...
Imarticus Learning, a professional education company, has announced an institutional partnership initiative to enable ...
Oral cancer remains a serious global health concern due to its high morbidity and mortality rates, primarily caused by late-stage diagnosis. The presence of oral potentially malignant disorders (OPMDs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results